Aptevo Therapeutics Inc
NASDAQ:APVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aptevo Therapeutics Inc
NASDAQ:APVO
|
US |
|
Crescent Capital BDC Inc
NASDAQ:CCAP
|
US |
|
China Logistics Property Holdings Co Ltd
HKEX:1589
|
CN |
|
Global Menkul Degerler AS
IST:GLBMD.E
|
TR |
Aptevo Therapeutics Inc
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 54 full-time employees. The company went IPO on 2016-07-20. The firm is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The company has developed two platform technologies, such as ADAPTIR and ADAPTIR-FLEX for rational design of precision immune modulatory drugs. Its lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is being developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific CD3xCD123 ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate employing a mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 54 full-time employees. The company went IPO on 2016-07-20. The firm is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The company has developed two platform technologies, such as ADAPTIR and ADAPTIR-FLEX for rational design of precision immune modulatory drugs. Its lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is being developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific CD3xCD123 ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate employing a mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
